Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Julie M. Vose, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Izidore S. Lossos, MD, Annette Ervin-Haynes, DO, Kenichi Takeshita, MD, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2570.

https://doi.org/10.1182/blood.V110.11.2570.2570

Published: 2007

Journal Articles

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Thomas E. Witzig, MD, Craig B. Reeder, MD, Jonathan Polikoff, MD, Naveed M. Chowhan, MD, Isaac Esseessee, MD, Richard Greenberg, MD, Hermant Patel, MD, Davood Vafai, MD, Peter H. Wiernik, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Myron Czuczman, MD

Blood (2007) 110 (11): 2572.

https://doi.org/10.1182/blood.V110.11.2572.2572

Published: 2007

Journal Articles

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Timothy D. Moore, MD, Craig B. Reeder, MD, Craig E. Cole, MD, Glen Justice, MD, Henry P. Kaplan, MD, Michael Voralia, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2007) 110 (11): 2560.

https://doi.org/10.1182/blood.V110.11.2560.2560

Published: 2007

Journal Articles

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Joseph M. Tuscano, MD, Izidore S. Lossos, MD, Glen Justice, MD, Julie M. Vose, MD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2563.

https://doi.org/10.1182/blood.V110.11.2563.2563

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Izidore S. Lossos, MD, Peter H. Wiernik, MD, Glen Justice, MD, Joseph M. Tuscano, MD, Craig E. Cole, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2564.

https://doi.org/10.1182/blood.V110.11.2564.2564

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Peter H. Wiernik, MD, Izidore S. Lossos, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Craig E. Cole, MD, Kyle McBride, MS, Kenton Wride, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2565.

https://doi.org/10.1182/blood.V110.11.2565.2565

Published: 2007

Journal Articles

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Peter H. Wiernik, MD, Izidore Lossos, MD, Joseph Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD,PhD, Thomas M. Habermann, MD

Blood (2006) 108 (11): 531.

https://doi.org/10.1182/blood.V108.11.531.531

Published: 2006

Journal Articles

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Christine Chen, MD, Donna E. Reece, MD, David Siegel, MD, Ruben Niesvizky, MD, Ralph Vincent Boccia, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, David Irwin, MD, Jonathan Polikoff, MD, Shaji Kumar, MD, Richard A. Gams, MD, Laurie Kenvin, RN,BS, Dale McElveen, MBA, Angela Hu, MS, Dennis Pietronigro, PhD, Robert D. Knight, MD, Jerome B. Zeldis, MD,PhD

Blood (2006) 108 (11): 3556.

https://doi.org/10.1182/blood.V108.11.3556.3556

Published: 2006

Journal Articles

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Henry P. Kaplan, MD, Jeffrey Lee Wolf, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2006) 108 (11): 2482.

https://doi.org/10.1182/blood.V108.11.2482.2482

Published: 2006

NARROW

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only